Transcriptomics

Dataset Information

0

Small-molecule Activators Specific to Adenine Base Editors through Blocking Canonical TGF-beta Pathway


ABSTRACT: ABEs were developed to catalyze an A-to-G conversion, thus holding therapeutic potentials for treating the major class of human pathogenic SNPs. However, robust and precise editing at diverse genome loci in a controllable manner remains challenging. Here, through a high-throughput chemical screen of ~ 8,000 small molecules, we identified and validated a spectrum of small molecules that target the canonical TGF-beta pathway as ABE activators. Among those, SB505124, a selective ALK5 inhibitor, promotes ABE editing most. Treating cells with SB505124 dramatically enhanced on-target editing at multiple genome loci, including the refractory regions, while exhibiting little effect on off-target conversion on the genome, eliminating the major concern for clinical applications. Furthermore, SB505124 facilitates the editing of disease-associated genes in vitro and in vivo. Intriguingly, SB505124 serves as a specific activator by selectively promoting the activity of ABEs, rather than CBEs or Cas9. Our finding equips the ABE with precise chemical control, and more importantly, reveals a so-far-unreported role of the canonical TGF-beta pathway on gene editing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE208182 | GEO | 2022/09/20

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-09-14 | GSE242012 | GEO
2024-03-11 | GSE260967 | GEO
2022-01-01 | GSE185496 | GEO
2022-01-01 | GSE185495 | GEO
2019-07-11 | GSE129893 | GEO
2019-07-11 | GSE129889 | GEO
2021-04-13 | GSE168364 | GEO
2021-04-13 | GSE168363 | GEO
2022-08-25 | GSE211876 | GEO
2020-11-12 | GSE161380 | GEO